Established in 2004, the Resource Tracking for HIV Prevention Research & Development Working Group (“Working Group”) comprises AVAC, IAVI and UNAIDS, with AVAC serving as the secretariat.
The Working Group has employed a standardized and comprehensive methodology to generate HIV prevention research and development (R&D) estimates, and to track investment trends for biomedical HIV prevention options, including HIV vaccines, microbicides, pre-exposure prophylaxis (PrEP), treatment as prevention (TasP), voluntary medical male circumcision (VMMC), female condoms, prevention of vertical transmission (PVT) and multipurpose prevention technologies. The Working Group also separately tracks expenditures in HIV cure research and in the development of vaccines and diagnostics for a wide range of sexually transmitted infections.
By generating investment estimates that can be compared from year to year and across prevention options, funding sources and strategies, the Working Group helps assess the impact of relevant public policies and marshals data for use in advocacy.
This year’s report was prepared by Shiva Mozaffarian, Navita Jain and Grace Yoon (AVAC), with support from Jenni Maple (IAVI), Jaime Atienza Azcona and Deepak Mattur (UNAIDS), and Kevin Fisher and Mitchell Warren (AVAC).
This analysis is made possible by the generous support of several donors, including the Bill and Melinda Gates Foundation, and the American people through the US President’s Emergency Plan for AIDS Relief (PEPFAR) and the US Agency for International Development (USAID) as part of the Coalition to Accelerate and Support Prevention Research (CASPR) project. The contents are the responsibility of AVAC and the Working Group, and do not necessarily reflect the views of PEPFAR, USAID or the United States Government. AVAC and the Working Group do not accept funding from the pharmaceutical industry.
Resource Tracking for HIV Prevention R&D Working Group